Olumiant has a boxed warning, the strictest warning from the US Food and Drug Administration (FDA). It has this warning because it may increase the risk of: 1 Serious infections leading to ...

Eli Lilly and Incyte's JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients when added to other drugs, according to new results from the UK RECOVERY trial.

Eli Lilly's JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 patients, but had a significant effect on mortality, a secondary endpoint.

The U.S. Food and Drug Administration (FDA) recently approved baricitinib (Olumiant), a pill that is taken once a day. Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that ...